SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRANCHINI, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.814
EU - Europa 7.739
AS - Asia 6.273
SA - Sud America 869
Continente sconosciuto - Info sul continente non disponibili 406
AF - Africa 174
OC - Oceania 12
Totale 26.287
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.466
FI - Finlandia 3.937
SG - Singapore 2.334
IT - Italia 1.600
CN - Cina 1.476
VN - Vietnam 732
BR - Brasile 659
DE - Germania 518
HK - Hong Kong 474
PL - Polonia 313
GB - Regno Unito 297
UA - Ucraina 240
BD - Bangladesh 226
TR - Turchia 210
FR - Francia 206
JP - Giappone 192
CA - Canada 188
IN - India 160
ID - Indonesia 139
SE - Svezia 135
RU - Federazione Russa 132
MX - Messico 109
NL - Olanda 79
AR - Argentina 76
ZA - Sudafrica 69
IQ - Iraq 51
ES - Italia 45
PK - Pakistan 39
EC - Ecuador 35
BE - Belgio 34
CZ - Repubblica Ceca 29
MY - Malesia 27
CO - Colombia 25
VE - Venezuela 25
CL - Cile 24
MA - Marocco 24
NO - Norvegia 24
LT - Lituania 21
SA - Arabia Saudita 21
AT - Austria 20
DK - Danimarca 19
RO - Romania 18
IR - Iran 17
PH - Filippine 17
UZ - Uzbekistan 17
AE - Emirati Arabi Uniti 16
IE - Irlanda 16
KE - Kenya 16
TW - Taiwan 16
JO - Giordania 14
DZ - Algeria 13
ET - Etiopia 12
NP - Nepal 12
CH - Svizzera 11
JM - Giamaica 11
KR - Corea 11
AU - Australia 10
EG - Egitto 10
EU - Europa 10
AZ - Azerbaigian 9
IL - Israele 9
CR - Costa Rica 8
NG - Nigeria 7
PT - Portogallo 7
PY - Paraguay 7
TH - Thailandia 7
TN - Tunisia 7
UY - Uruguay 7
AL - Albania 6
DO - Repubblica Dominicana 6
GE - Georgia 6
PE - Perù 6
TT - Trinidad e Tobago 6
GR - Grecia 5
KZ - Kazakistan 5
LB - Libano 5
BH - Bahrain 4
BO - Bolivia 4
GT - Guatemala 4
HN - Honduras 4
HR - Croazia 4
KG - Kirghizistan 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
KW - Kuwait 3
PS - Palestinian Territory 3
SV - El Salvador 3
AF - Afghanistan, Repubblica islamica di 2
AO - Angola 2
BY - Bielorussia 2
EE - Estonia 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
OM - Oman 2
Totale 25.857
Salva come PNG Salva come JPEG
Città #
Helsinki 3.841
Singapore 1.418
Ashburn 1.139
Dallas 1.060
San Jose 841
Chandler 570
Santa Clara 535
Fairfield 505
Beijing 461
Hong Kong 445
Woodbridge 441
Ferrara 364
New York 325
Warsaw 305
Council Bluffs 304
Houston 298
Ann Arbor 278
Ho Chi Minh City 248
Los Angeles 238
Seattle 222
Wilmington 222
Jacksonville 218
Tokyo 181
Cambridge 173
Hanoi 167
Munich 161
Milan 139
Izmir 121
Princeton 119
Jakarta 106
Lauterbourg 104
Nanjing 101
Shanghai 99
Dearborn 88
São Paulo 88
Rome 73
Toronto 69
Boardman 68
Orem 65
The Dalles 63
Bremen 62
Mexico City 62
London 61
Denver 56
Montreal 56
Brooklyn 48
Atlanta 47
San Diego 47
Turku 43
Redwood City 41
Chennai 39
Chicago 39
Frankfurt am Main 39
Johannesburg 39
Phoenix 38
Bologna 37
Florence 36
Nanchang 36
Falls Church 35
Shenyang 34
Poplar 33
Buffalo 32
San Francisco 32
Guangzhou 31
Tianjin 31
Da Nang 29
Haiphong 29
Manchester 29
Brussels 26
Falkenstein 26
Moscow 26
Hefei 25
Amsterdam 23
Baghdad 23
Dong Ket 23
Rio de Janeiro 22
Boston 21
Hebei 21
Jiaxing 21
Nuremberg 21
Auburn Hills 20
San Mateo 20
Changsha 19
Mumbai 19
Ankara 18
Jinan 18
Paris 18
Stockholm 18
Washington 18
Biên Hòa 17
Brno 17
Columbus 17
Naples 17
Oslo 17
Hangzhou 16
Kunming 16
Tashkent 16
Charlotte 15
Hải Dương 15
Norwalk 15
Totale 18.028
Salva come PNG Salva come JPEG
Nome #
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 2.871
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 2.054
La sanificazione delle degenze ospedaliere: nuove strategie per la riduzione delle infezioni correlate all’assistenza sanitaria 467
La sanificazione delle degenze ospedaliere: nuove strategie a supporto della riduzione delle infezioni correlate all’assistenza sanitaria 414
Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation 361
Il sistema di sanificazione PCHS Probiotic Cleaning Hygien System: risultati delle indagini sperimentali in vitro e in campo 357
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 312
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 311
The carboxyl-terminal region of coagulation factors: role in biosynthesis and function of FVII and FX 308
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 294
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 291
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 276
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties 275
Hard surface biocontrol in hospitals using microbial-based cleaning products 271
PCHS (Probiotic Hygiene Cleaning System) Protocol: reduction of hospital environmental impact with a new and innovative technology for cleaning in Ferrara University Hospital 269
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 248
Chronic sleep deprivation markedly reduces coagulation factor VII expression 246
Reduction of the microbial load on hospital surfaces through probiotic-based cleaning procedures: a new strategy to control nosocomial infections 244
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 243
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 241
I probiotici: aspetti generali e valutazioni sulla sicurezza d’impiego 238
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 236
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 224
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 219
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 217
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 215
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 213
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 211
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 207
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 204
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 198
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 197
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 197
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 196
Characterization of PAR-mediated signaling induced by activated coagulation factor X mutants 193
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 193
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 189
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 188
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 186
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 184
An integrated multi-tool analysis contributes elements to interpreting unclassified factor IX missense variants associated with haemophilia B 183
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 182
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 181
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 180
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 180
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 176
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 175
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 174
An engineered factor X variant as a novel by-passing agent for hemophilia 169
Improved intracellular processing of protein variants as a personalized therapeutic approach for Haemophilia 169
F9 genotype and PK hemophilia B international study (GEPKHIS) 169
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 169
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 167
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 166
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 165
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 164
Comparative Analysis Of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B- domain Favours Readthrough- mediated Protein Output 162
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 162
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 162
Hemostasis gene expression of the internal jugular and saphenous veins 160
Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches 159
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 158
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 158
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 157
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 157
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 157
Exploring spontaneous readthrough over recurrent F8 nonsense mutations: potential correlation with inhibitor risk? 150
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 149
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 146
A recoded view on the F9 p.Cys178Ter pathogenic mechanism 146
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 146
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 145
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 144
Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies 143
Academic Editor per la rivista PLoS One 142
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 140
A new type 1 von Willebrand Disease (VWD) characterized by increased clearance of von Willebrand Factor (VWF) due to the heterozygous p.P1127S mutation: clinical phenotype and pathogenic mechanisms 135
Translation termination codons in protein synthesis and disease 134
MOLECULAR MECHANISMS AND THERAPEUTIC APROACHES FOR RESTORATION OF mRNA TRANSCRIPTION, MATURATION AND TRANSLATION IN INHERITED COAGULATION FACTOR DEFICIENCIES 134
“Compensatory” aberrant splicing supports residual expression levels in severe coagulation factor VII deficiency 133
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 133
The FVII R402X nonsense mutation, associated with an asymptomatic phenotype, is responsible for small amounts of circulating protein with improved coagulant activity 132
A factor X variant with engineered activation peptide as innovative by-passing agent for haemophilia 132
Effects of Partial Chronic Sleep Deprivation on the Mouse Blood Coagulation Cascade. 131
Engineered transcription factors (TALE-TF) as potential therapeutic strategy for coagulation factor deficiencies caused by promoter mutations 128
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity 126
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 125
Next generation factor VIIa with enhanced half-life 123
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations 123
Genotype and PK Hemophilia B International Study (GePKHIS) - A progress Report 120
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 118
Naturally occurring truncated proteins: decreased protein secretion and increased activity result in asymptomatic coagulation factor deficiency 111
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 108
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 108
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 105
Engineered suppressor tRNAs as a novel correction approach for recurrent hemophilia A-causing nonsense mutations 103
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 103
Associate Editor per la rivista Frontiers in Pediatrics - sezione Genetic Disorders 99
Mapping of inhibitory antibodies directed to the carboxy-terminus of FVIIa in severe FVII deficiency with elongated C-terminal variant (p.A354V-p.P464Hfs†) 98
Tailored collagen binding confers distinct functional properties to engineered factor IX fusion proteins in hemophilia B mouse model 97
Totale 23.129
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 698
Totale 104.524
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.011 0 139 37 36 82 72 49 48 35 84 74 355
2022/20231.242 132 144 50 174 179 158 77 79 135 11 58 45
2023/2024856 63 67 44 32 54 156 41 62 29 33 44 231
2024/20253.349 102 78 302 108 394 371 78 90 523 383 507 413
2025/202614.086 944 550 1.259 1.308 1.385 652 1.158 474 4.600 963 490 303
2026/2027713 418 295 0 0 0 0 0 0 0 0 0 0
Totale 26.287